Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
03/09/2026 15:47
BRIEF-Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co Sept 3 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:
MILESTONE PHARMACEUTICALS ANNOUNCES NMPA APPROVAL OF ETRIPAMIL NASAL SPRAY FOR PSVT IN CHINA, MARKING FIRST REGULATORY APPROVAL OF ETRIPAMIL OUTSIDE OF THE UNITED STATES
MILESTONE PHARMACEUTICALS - NMPA APPROVAL TRIGGERS $2 MILLION MILESTONE PAYMENT TO MILESTONE PHARMACEUTICALS
MILESTONE PHARMACEUTICALS - EVEREST MEDICINES HOLDS EXCLUSIVE LICENSE FOR ETRIPAMIL NASAL SPRAY IN GREATER CHINA
MILESTONE PHARMACEUTICALS - UNDER AGREEMENT WITH EVEREST, CO ELIGIBLE FOR UP TO $98 MILLION IN MILESTONES AND UP TO 18% ROYALTIES IN GREATER CHINA
Source text: ID:nGNX7R3fH0
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview